Notice of Securities Fraud Lawsuit Against Agilon Health, Inc.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy AGL?
Source: Globenewswire
- Lawsuit Background: A class action lawsuit has been filed on behalf of investors who purchased Agilon Health securities between February 26, 2025, and August 4, 2025, alleging the company issued unrealistic 2025 financial guidance amidst known industry headwinds, resulting in investor losses.
- Leadership Change: On August 4, 2025, Agilon announced the resignation of CEO Steven Sell, classified as a termination without 'cause', which heightened market concerns regarding the company's future outlook.
- Suspension of Financial Guidance: On the same day, Agilon's financial report revealed that due to more severe industry headwinds than expected, the company decided to suspend its previously issued 2025 financial guidance, causing the stock price to plummet by 51.6% from $1.82 to $0.88 the following day.
- Investor Action Recommendation: Investors are advised to apply by March 2, 2026, to become lead plaintiffs to represent the class's interests in the lawsuit, as courts typically appoint individual investors to influence litigation strategy and settlement decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGL
Wall Street analysts forecast AGL stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.404
Low
0.88
Averages
0.88
High
0.88
Current: 0.404
Low
0.88
Averages
0.88
High
0.88
About AGL
agilon health, inc. is a healthcare company. It enables primary care physicians (PCP) to be the agents for change in the communities they serve. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of its physician partners’ attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform is holistic in supporting the rapid transition to a Total Care Model with technology, people, process and capital.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Class Action Notice: Rosen Law Firm reminds investors who purchased Agilon Health (NYSE:AGL) securities between February 26, 2025, and August 4, 2025, that they must apply to be lead plaintiff by March 2, 2026, or risk losing the opportunity to represent other investors in the class action.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to join the lawsuit.
- Lawsuit Background: The lawsuit alleges that Agilon Health made false and misleading statements during the class period, resulting in investor losses when the truth emerged, potentially impacting the company's reputation and future stock performance.
- Law Firm Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling such cases.
See More
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Agilon Health and certain executives, alleging violations of federal securities laws from February 26 to August 4, 2025, seeking to recover losses for investors.
- False Statement Allegations: The complaint claims that Agilon executives issued unrealistic guidance for 2026, fully aware of significant industry headwinds, which misled investors regarding the company's prospects.
- Overstated Financial Impact: The lawsuit further alleges that Agilon exaggerated the immediate positive financial impacts from its 'strategic actions', misleading investors about the company's operations and future outlook.
- Investor Action Recommendation: Affected investors are encouraged to apply to be lead plaintiffs by March 2, 2026, to participate in potential recovery, with attorney fees only charged upon success, thereby reducing investor risk.
See More
- Investor Loss Reminder: Faruq & Faruqi's Securities Litigation Partner Josh Wilson is urging investors who suffered losses exceeding $50,000 in agilon health between February 26, 2025, and August 4, 2025, to contact him directly to discuss their legal options, highlighting the firm's commitment to investor rights.
- Legal Action Notification: The firm is investigating potential claims against agilon health, inc. and reminds investors of the March 2, 2026, deadline to seek the role of lead plaintiff in a federal securities class action filed against the company, indicating the urgency of legal proceedings.
- Contact Information Provided: Investors can reach Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to ensure timely legal consultation and support, reflecting the firm's emphasis on client service.
- Class Action Context: The initiation of this class action indicates the legal risks faced by agilon health, which could negatively impact its stock price and market confidence, prompting investors to closely monitor developments to protect their interests.
See More
- Class Action Initiated: Pomerantz LLP has filed a class action lawsuit against Agilon Health, Inc., alleging securities fraud and other unlawful business practices, with investors advised to apply as Lead Plaintiff by March 2, 2026.
- Stock Price Plunge: Following the release of financial results and executive changes on August 5, 2025, Agilon's stock price fell by $0.94, or 51.52%, closing at $0.88, indicating strong market concerns regarding the company's outlook.
- Financial Guidance Suspension: Agilon announced the suspension of its previously issued full-year 2025 financial guidance in its Q2 2025 report, reflecting that industry headwinds are more severe than expected, which may undermine investor confidence moving forward.
- Executive Change Impact: The resignation of CEO Steven Sell on August 4, 2025, could lead to significant shifts in Agilon's strategic direction, further intensifying market skepticism about its future performance.
See More
- Lawsuit Background: A class action lawsuit has been filed on behalf of investors who purchased Agilon Health securities between February 26, 2025, and August 4, 2025, alleging the company issued unrealistic 2025 financial guidance amidst known industry headwinds, resulting in investor losses.
- Leadership Change: On August 4, 2025, Agilon announced the resignation of CEO Steven Sell, classified as a termination without 'cause', which heightened market concerns regarding the company's future outlook.
- Suspension of Financial Guidance: On the same day, Agilon's financial report revealed that due to more severe industry headwinds than expected, the company decided to suspend its previously issued 2025 financial guidance, causing the stock price to plummet by 51.6% from $1.82 to $0.88 the following day.
- Investor Action Recommendation: Investors are advised to apply by March 2, 2026, to become lead plaintiffs to represent the class's interests in the lawsuit, as courts typically appoint individual investors to influence litigation strategy and settlement decisions.
See More
- Klarna Class Action: A class action lawsuit against Klarna Group plc alleges that during its September 2025 IPO, the company failed to disclose the risk of increasing loss reserves, misleading investors about its business prospects, with a lead plaintiff deadline of February 20, 2026.
- agilon Health Lawsuit: The class action against agilon health, inc. claims that from February to August 2025, the company issued unrealistic financial guidance without disclosing significant industry headwinds, requiring investors to act by March 2, 2026.
- Fermi Inc. Litigation: Fermi Inc. faces a class action lawsuit alleging that from October to December 2025, it overstated tenant demand and relied heavily on a single tenant's funding commitment, with a lead plaintiff deadline of March 6, 2026.
- Legal Consultation Advice: Investors are encouraged to contact the Law Offices of Howard G. Smith to understand their legal rights in these class actions, highlighting the potential risks for the companies involved and the importance of investor rights protection.
See More







